NCT02392468View on ClinicalTrials.gov

Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

April 15, 2015

Primary Completion Date

August 3, 2017

Study Completion Date

August 10, 2017

Conditions
SchizophreniaAlzheimer Disease
Interventions
DRUG

Placebo matching BI 409306 25 mg

Film-coated tablet

DRUG

Placebo matching BI 409306 50 mg

Film-coated tablet

DRUG

BI 409306 25 mg

Film-coated tablet

DRUG

BI 409306 50 mg

Film-coated tablet

Trial Locations (3)

78754

Community Clinical Research, Inc., Austin

92037

University of California San Diego, La Jolla

07724

Memory Enhancement Center of America, Inc., Eatontown

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02392468 - Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers | Biotech Hunter | Biotech Hunter